Baron and Budd Examining Internal Company Memo Connected to the GranuFlo Lawsuit An internal company memo sent by Fresenius Medical Care allegedly shows that Fresenius was aware of GranuFlo's risks Business Wire DALLAS -- July 30, 2013 Baron and Budd, a nationally recognized plaintiffs’ law firm, is handling cases related to the GranuFlo lawsuit. Currently, Baron and Budd is examining the internal company memo sent out by Fresenius Medical Care on November 4, 2011. This memo may help to show that Fresenius Medical Care allegedly understood the dangers associated with their popular dialysis product and chose to not alert their entire consumer base. Fresenius Medical Care is the leading producer of products and services for kidney dialysis and over one-third of the more than 400,000 Americans who undergo dialysis treatments each year go to Fresenius clinics for their dialysis treatment. Unfortunately, the memo reveals a potential consequence of GranuFlo use: that dialysis patients who are given GranuFlo may develop excess levels of bicarbonate in their blood, leading to a four to six times increase in the likelihood of cardiac arrest.Additionally, out of the many dialysis products on the market, GranuFlo, along with its sister drug NaturaLyte, is particularly prone to produce excess levels of bicarbonate. “Patients undergoing dialysis are already struggling with health issues,” said Russell Budd, president and managing shareholder at Baron and Budd. “They shouldn't have to worry even more about their dialysis treatments." The internal company memo allegedly shows that Fresenius Medical Center was aware of the increased levels of bicarbonate risk associated with GranuFlo. Had Fresenius Medical Center followed the internal company memo with a wide scale alert to the entire patient list, including patients who used the GranuFlo product at non-Fresenius dialysis centers, than dialysis patients might have avoided serious health complications. If you or someone you know has received GranuFlo treatments and suffered serious health issues as a result, contact our GranuFlo lawyers today at 1.866.844.4556 or email us at email@example.com. For more information about GranuFlo lawyers and Baron and Budd, visit Baron and Budd’s website here:http://baronandbudd.com/areas-of-practice/pharmaceuticals/granuflo-lawyer/. For more than 35 years, Baron and Budd lawyers have been protecting the rights of people who have been harmed by negligent companies. The firm has an established track record of success. Recently, Baron and Budd lawyers were involved in litigation surrounding the diabetes drug Avandia. Baron and Budd represented more than 7,000 patients harmed by Avandia use, and currently represents numerous states in lawsuits against Avandia manufacturer GlaxoSmithKline. In the 1990s, the firm was closely involved in litigation surrounding the once popular diet drug Fen-Phen. The resulting global settlement was valued at over $1.275 billion. In addition to GranuFlo,Baron and Budd is handling lawsuits related to harms caused by Lipitor, Actos and Transvaginal Mesh. About Baron & Budd, P.C. The law firm of Baron & Budd, P.C., with offices in Dallas, Baton Rouge, Austin and Los Angeles, is a nationally recognized law firm with a 35-year history of "Protecting What's Right" for people, communities and businesses harmed by negligence. Baron & Budd's size and resources enable the firm to take on large and complex cases. The firm represents individuals, governmental and business entities in areas as diverse as water contamination, Gulf oil spill, Qui Tam, California Proposition 65 violations, dangerous medications and medical devices, Chinese drywall, insurance claims, consumer fraud, securities fraud and asbestos-related illnesses such as mesothelioma. Contact: Baron & Budd Susan Knape, 214-629-0596 firstname.lastname@example.org or Amanda Billo, 214-991-1051 email@example.com
Baron and Budd Examining Internal Company Memo Connected to the GranuFlo Lawsuit
Press spacebar to pause and continue. Press esc to stop.